IL6 and cancer: We demonstrated that cancer-derived interleukin-6 (IL-6) stimulates STAT3-dependent, nuclear factor-κB-mediated indoleamine 2,3-dioxygenase (IDO) upregulation in eMDSCs which triggers immunosuppressive effects of eMDSCs (Yu et al., 2014).